Bayer AG (Bayer) is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company's product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
Headquarters
Germany
Address
Kaiser-Wilhelm-Allee 1, Leverkusen, Nordrhein-Westfalen, 51373
Website
www.bayer.com
Telephone
49 214 301
No of Employees
102,048
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BAYN (ETR)
Revenue (2022)
$53.4B
15.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
315%
(2022 vs 2021)
Market Cap*
$47.3B
Net Profit Margin (2022)
XYZ
260.4%
(2022 vs 2021)
* As of and is in US$
Bayer AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Product Categories:- | Business - | - |
| Healthcare | IT Infrastructure and Applications | Xarelto |
| Prescription Drugs | Procurement and Logistics | Yasmin |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In September, the company and Hologic Inc entered into a partnership to deliver contrast-enhanced-mammography solutions to enhance the detection of breast cancer in multiple countries across Canada, European, and Asia Pacific regions. |
| 2023 | Financing Agreements | In August, the company invested EUR220 million in research and development at its Monheim site. |
| 2023 | Contracts/Agreements | In August, the company and Pairwise entered into a new five-year, multi-million Dollar agreement to focus on innovations in short-stature corn. |
Competitor Comparison
| Key Parameters | Bayer AG | Pfizer Inc | Johnson & Johnson | BASF SE | F. Hoffmann-La Roche Ltd |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United States of America | Germany | Switzerland |
| City | Leverkusen | New York | New Brunswick | Ludwigshafen Am Rhein | Basel |
| State/Province | Nordrhein-Westfalen | New York | New Jersey | Rheinland-Pfalz | - |
| No. of Employees | 102,048 | 83,000 | 152,700 | 111,315 | 103,613 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William N. Anderson | Chief Executive Officer | Senior Management | 2023 | - |
| Wolfgang Nickl | Chief Financial Officer | Senior Management | 2018 | 54 |
| Sarena Lin | Director - Labor; Chief Transformation and Talent Officer | Senior Management | 2021 | 52 |
| Heike Prinz | Labor Director; Chief Talent Officer | Senior Management | 2023 | - |
| Norbert Winkeljohann | Chairman | Non Executive Board | 2020 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward